Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.

Summary What is known and Objective: Tacrolimus (TAC) is metabolized mainly by the CYP3A subfamily and extruded into the intestine by P-glycoprotein, which is encoded by the ABCB1 gene. Several studies have suggested that the CYP3A5*3 genotype influenced the pharmacokinetics (PK) of TAC. The CYP3A4*...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Clinical Pharmacy & Therapeutics Vol. 36; no. 5; pp. 614 - 625
Autores principales: Shi, X.-J., Geng, F., Jiao, Z., Cui, X.-Y., Qiu, X.-Y., Zhong, M.-K.
Formato: equations & formulas research tables/charts Journal Article
Publicado: Wiley-Blackwell Oct2011
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104685569&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104685569
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        02694727
        EV4
      jtl: Journal of Clinical Pharmacy & Therapeutics
      issn: 02694727
      maglogo: Y
    pubinfo:
      dt: Oct2011
      vid: 36
      iid: 5
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        104685569
        65430247
        10.1111/j.1365-2710.2010.01206.x
        NLM21916909
        104685569
      ppf: 614
      ppct: 11
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
      aug:
        au:
          Shi, X.-J.
          Geng, F.
          Jiao, Z.
          Cui, X.-Y.
          Qiu, X.-Y.
          Zhong, M.-K.
        affil: Clinical Pharmacy Laboratory, Huashan Hospital, Fudan University, Shanghai, China
      sug:
        subj:
          Genotype
          Antibiotics, Macrolide Pharmacokinetics
          Chinese Persons
          Antibiotics, Macrolide Metabolism
          Polymorphism, Genetic Drug Effects
          Immunosuppressive Agents Pharmacokinetics
          Biological Availability
          Antibiotics, Macrolide Blood
          Mass Spectrometry
          Chromatography, Liquid
          Sequence Analysis
          Antibiotics, Macrolide Administration and Dosage
          Administration, Oral
          Data Analysis Software
          Analysis of Covariance
          Chi Square Test
          Models, Statistical
          Human
          Male
          Female
          Adult
          Descriptive Statistics
          Univariate Statistics
          Funding Source
          Adult: 19-44 years
          Male
          Female
      ab: Summary What is known and Objective: Tacrolimus (TAC) is metabolized mainly by the CYP3A subfamily and extruded into the intestine by P-glycoprotein, which is encoded by the ABCB1 gene. Several studies have suggested that the CYP3A5*3 genotype influenced the pharmacokinetics (PK) of TAC. The CYP3A4*18B and CYP3A5*3 alleles are clinically important in Chinese subjects because of their relatively high frequency. The present study aimed at evaluating the effects of ABCB1 (C1236T-G2677T/A-C3435T), CYP3A4*18B and CYP3A5*3 genetic polymorphisms on TAC PK in healthy Chinese subjects. Methods: Data were obtained from a comparative bioavailability study of oral TAC formulations ( n = 22). TAC whole blood concentrations were measured by LC-MS/MS. Genetic polymorphisms were determined using a direct sequencing method. Nonlinear mixed-effects modelling (NONMEM) was performed to assess the effect of genotypes and demographics on TAC PKs. Results and Discussion: Both CYP3A4*18B and CYP3A5*3 polymorphisms affected the TAC PK, whereas ABCB1 genetic polymorphisms and other demographic characteristics did not. The combined genotypes of CYP3A4*18B and CYP3A5*3 had a greater impact than either genotype alone, and they were estimated to account for 28·4% of the inter-subject variability of apparent clearance (CL/ F) by NONMEM. The CL/ F in subjects with CYP3A4*1/*1-CYP3A5*3/*3 was 10·3 L/h and was 48·5% in those not carrying CYP3A4*1/*1-CYP3A5*3/*3. What is new and Conclusion: This is the first study to extensively explore the influence of CYP3A4*18B, CYP3A5*3 and ABCB1 genetic polymorphisms on TAC PK in healthy Chinese subjects. The results demonstrated that subjects with a combined genotype of CYP3A4*1/*1-CYP3A5*3/*3 may require lower TAC doses to achieve target concentration levels and further investigation is needed in larger populations to confirm the clinical benefits.
      pubtype: Academic Journal
      doctype:
        equations & formulas
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N